BioGaia AB has signed an agreement with the British pharmaceutical company Forest Laboratories UK Limited, a subsidiary of Forest Pharmaceuticals Inc. The agreement gives Forest the exclusive rights to sell BioGaia's Reuteri Drops in Great Britain and Ireland.
BioGaia's patented Reuteri Drops are a simple, safe and effective way to improve the digestive health of infants. The company has, in several clinical studies, shown the Drops' positive effect on a number of stomach problems including colic.
Forest Laboratories UK, the market leader in colic products in the UK and Ireland, is a subsidiary to Forest Laboratories Inc. USA, a publicly listed pharmaceutical company with a turnover of just over 3 billion dollars.
"With Forest's strong marketing organisation and its well established products for children we have found an excellent partner that can market the Reuteri Drops in an important market," said Peter Rothschild Managing Director, BioGaia AB. Launch is expected to take place during 2006.
"Our market research has shown that there is a strong need for a natural product of this kind for infants with stomach problems. We are looking forward to working with this innovative company, BioGaia both on Reuteri Drops and future products," said Raymond Stafford CEO of Forest Laboratories Europe.